SCHEMBL167223

SCHEMBL167223

CCCCCCCCCCC(CC(O)CO)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.62
GRIK2 Q13002 2/20 0.62
SLC1A2 P43004 2/20 0.59
SLC1A1 P43005 2/20 0.59
GPR84 Q9NQS5 7/20 0.53
FFAR1 O14842 2/20 0.53
SLC1A3 P43003 1/20 0.51
CA2 P00918 2/20 0.50
MAPK1 P28482 1/20 0.50
FFAR4 Q5NUL3 1/20 0.49
MAPT P10636 1/20 0.47
LCK P06239 1/20 0.47
PPARD Q03181 1/20 0.47
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47
ACE2 Q9BYF1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425590 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL28996904 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL168065 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
Dodecane SCHEMBL1325927 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL1237976 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL23854065 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL165538 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL17646228 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL1512830 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84
SCHEMBL4962689 1.00 GRIK1 (0.62) GRIK1GRIK2SLC1A2SLC1A1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3075401-B1 PRESERVATION FOR COSMETIC, TOILETRY AND PHARMACEUTICAL COMPOSITIONS INOLEX INVESTMENT CORP (US) 2024-04-03 EP claimed
CN-117137814-A Cosmetic composition with affinity to skin microbiome 株式会社LG生活健康 2023-12-01 CN claimed
CN-111885993-B Liposomal composition comprising cultured root extract of mountain ginseng and composition for personal beauty or personal care containing the same 株式会社韩国化妆品制造 2023-04-04 CN claimed
EP-4114182-A1 METHODS AND COMPOSITIONS FOR IMPROVING THE PROPERTIES AND PRODUCTIVITY OF PLANTS Apeel Technology, Inc. (US) 2023-01-11 EP claimed
EP-1809243-B2 AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA AS A PROPELLANT BOEHRINGER INGELHEIM INT (DE) 2022-06-08 EP claimed
US-20210298298-A1 METHODS AND COMPOSITIONS FOR IMPROVING THE PROPERTIES AND PRODUCTIVITY OF PLANTS APEEL TECHNOLOGY, INC. 2021-09-30 US claimed
CN-113316606-A Method for preparing superabsorbent polymer UPL有限公司 2021-08-27 CN claimed
WO-2021058158-A1 PRODUCT FOR DYEING KERATINOUS MATERIAL, CONTAINING AMINOSILICONE, A CHROMOPHORIC COMPOUND AND ETHOXYLATED FATTY ACID ESTER HENKEL AG & CO. KGAA (DE) 2021-04-01 WO claimed
EP-3006045-B3 Pharmaceutical formulations for the oral delivery of peptide or protein drugs CYPRUMED GMBH (AT) 2021-03-17 EP claimed
EP-2988731-B1 COMPOSITION FOR USE IN REDUCING SCAB FORMATION AND PROMOTING HEALING BIOGLAN AB (SE) 2021-02-17 EP claimed
EP-0754028-A1 NOVEL DEODORISING AND ANTI-MICROBIAL COMPOSITIONS FOR USE IN COSMETIC OR TOPICAL PREPARATIONS Beiersdorf Aktiengesellschaft (DE) 1997-01-22 EP claimed
EP-0483812-B1 Prevention of toxin production using absorbent products MCNEIL PPC INC (US) 1996-08-21 EP claimed
EP-0705605-A2 Use of fatty acid esters against superinfections Beiersdorf Aktiengesellschaft (DE) 1996-04-10 EP claimed
WO-1995026708-A2 NOVEL DEODORISING AND ANTI-MICROBIAL COMPOSITIONS FOR USE IN COSMETIC OR TOPICAL PREPARATIONS BEIERSDORF AG (DE) 1995-10-12 WO claimed
EP-0487524-B1 METHOD AND APPARATUS FOR DETERMINING NON-TRIGLYCERIDES IN OILS LIBRA LAB INC (US) 1995-05-10 EP claimed
EP-0451949-B1 Transparent stick compositions UNILEVER PLC (GB) 1994-09-14 EP claimed
EP-0402407-B1 TRANSDERMAL ESTRADIOL DELIVERY SYSTEM RIKER LABORATORIES INC (US) 1994-08-03 EP claimed
EP-0596284-A2 Antimycotic cosmetic and dermatological compositions containing fatty acid esters Beiersdorf Aktiengesellschaft (DE) 1994-05-11 EP claimed
EP-0376534-B1 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine RIKER LABORATORIES INC (US) 1993-12-15 EP claimed
EP-0219539-B1 TRANSDERMAL NITROGLYCERIN DELIVERY SYSTEM RIKER LABORATORIES, INCORPORATED (US) 1992-06-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210298298-A1 METHODS AND COMPOSITIONS FOR IMPROVING THE PROPERTIES AND PRODUCTIVITY OF PLANTS MGLL, AGL, GK GRIK1 1110/4885GRIK2 1070/4885SLC1A2 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.